Capital Impact Advisors LLC Acquires Shares of 47,281 Natera, Inc. $NTRA

Capital Impact Advisors LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 47,281 shares of the medical research company’s stock, valued at approximately $6,686,000. Natera makes up about 2.6% of Capital Impact Advisors LLC’s holdings, making the stock its 24th biggest position.

A number of other hedge funds also recently bought and sold shares of NTRA. Captrust Financial Advisors lifted its stake in Natera by 36.0% during the fourth quarter. Captrust Financial Advisors now owns 7,737 shares of the medical research company’s stock valued at $1,225,000 after buying an additional 2,048 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Natera in the fourth quarter worth approximately $242,000. Deutsche Bank AG lifted its position in shares of Natera by 26.6% in the fourth quarter. Deutsche Bank AG now owns 86,239 shares of the medical research company’s stock worth $13,652,000 after purchasing an additional 18,113 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Natera by 35.4% in the fourth quarter. Focus Partners Wealth now owns 5,519 shares of the medical research company’s stock worth $874,000 after purchasing an additional 1,442 shares in the last quarter. Finally, LRI Investments LLC purchased a new stake in shares of Natera in the fourth quarter worth approximately $29,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 6,092 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52. Following the transaction, the chief executive officer owned 169,400 shares in the company, valued at $23,683,814. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is owned by company insiders.

Natera Stock Performance

NASDAQ:NTRA opened at $176.37 on Wednesday. The stock’s 50 day moving average price is $154.63 and its 200 day moving average price is $153.87. Natera, Inc. has a 52 week low of $114.62 and a 52 week high of $183.00. The company has a market capitalization of $24.21 billion, a P/E ratio of -92.34 and a beta of 1.68.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the company posted ($0.30) EPS. The company’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on NTRA shares. Stephens reissued an “overweight” rating and issued a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Piper Sandler reissued an “overweight” rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Barclays reissued an “overweight” rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Finally, Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 price target for the company in a research report on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.